DK201300193U1 - Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner. - Google Patents

Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner.

Info

Publication number
DK201300193U1
DK201300193U1 DKBA201300193U DKBA201300193U DK201300193U1 DK 201300193 U1 DK201300193 U1 DK 201300193U1 DK BA201300193 U DKBA201300193 U DK BA201300193U DK BA201300193 U DKBA201300193 U DK BA201300193U DK 201300193 U1 DK201300193 U1 DK 201300193U1
Authority
DK
Denmark
Prior art keywords
vaccines
aluminum compounds
therapeutic products
composition
protein
Prior art date
Application number
DKBA201300193U
Other languages
English (en)
Inventor
Moehlen Michael
Weber Michael
Wruss Juergen
Schlegl Robert
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47294919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK201300193(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/054387 external-priority patent/WO2013135274A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of DK201300193U1 publication Critical patent/DK201300193U1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Opfindelsen angår en vandig sammensætning omfattende et protein eller et polypeptide-polysaccharide-konjugat og et aluminiumsalt. Opfindelsen angår endvidere vandige sammensætninger omfattende et protein og et aluminiumsalt, hvor sammensætningen omfatter mindre end 350 ppb tungmetal baseret på vægten af den vandige sammensætning. Den foreliggende opfindelse øger stabiliteten af poteinet eller polypeptidepolysaccharide- konjugatet i sammensætningen.
DKBA201300193U 2011-12-06 2013-12-09 Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner. DK201300193U1 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11192230 2011-12-06
PCT/EP2012/054387 WO2013135274A1 (en) 2012-03-13 2012-03-13 Aluminium compounds for use in therapeutics and vaccines
PCT/EP2012/074701 WO2013083726A1 (en) 2011-12-06 2012-12-06 Aluminium compounds for use in therapeutics and vaccines

Publications (1)

Publication Number Publication Date
DK201300193U1 true DK201300193U1 (da) 2014-01-17

Family

ID=47294919

Family Applications (6)

Application Number Title Priority Date Filing Date
DK12795830.4T DK2788023T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse i terapeutiske midler og vacciner
DK17185526.5T DK3269386T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse inden for behandling og i vacciner
DK20184308.3T DK3785730T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
DK16183076.5T DK3106176T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse i terapeutika og vacciner
DKBA201300194U DK201300194U1 (da) 2011-12-06 2013-12-09 Aluminiumhydroxidkoncentrat, fortrinsvis til anvendelse i fremstillingen af en vaccine
DKBA201300193U DK201300193U1 (da) 2011-12-06 2013-12-09 Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner.

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DK12795830.4T DK2788023T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse i terapeutiske midler og vacciner
DK17185526.5T DK3269386T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse inden for behandling og i vacciner
DK20184308.3T DK3785730T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
DK16183076.5T DK3106176T3 (da) 2011-12-06 2012-12-06 Aluminiumforbindelser til anvendelse i terapeutika og vacciner
DKBA201300194U DK201300194U1 (da) 2011-12-06 2013-12-09 Aluminiumhydroxidkoncentrat, fortrinsvis til anvendelse i fremstillingen af en vaccine

Country Status (15)

Country Link
EP (5) EP2788023B1 (da)
CY (1) CY1119927T1 (da)
DE (1) DE202012012768U1 (da)
DK (6) DK2788023T3 (da)
ES (2) ES2930458T3 (da)
FI (1) FI3785730T3 (da)
HR (1) HRP20171871T1 (da)
HU (1) HUE037325T2 (da)
LT (1) LT3106176T (da)
NO (1) NO3106176T3 (da)
PL (2) PL3106176T3 (da)
PT (2) PT3106176T (da)
RS (1) RS56709B1 (da)
SI (1) SI3106176T1 (da)
WO (1) WO2013083726A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
EP3188750B1 (en) * 2014-09-03 2020-03-11 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
BR112018012873A2 (pt) 2015-12-23 2018-12-04 Valneva Austria Gmbh vacina de vírus zika
MA47223A (fr) 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
US11484587B2 (en) 2017-09-21 2022-11-01 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
JP7443233B2 (ja) 2017-11-30 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
EP3820884A1 (en) 2018-07-13 2021-05-19 Valneva SE Method for rescuing and producing a virus in avian cells
AU2020277661A1 (en) 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
US20230218740A1 (en) * 2020-03-01 2023-07-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP4114463A4 (en) * 2020-03-01 2023-09-06 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
GB2592769B (en) 2020-03-01 2022-05-04 Valneva Austria Gmbh CpG-Adjuvanted SARS-CoV-2 virus vaccine
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021178318A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
WO2021205017A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
JP2024522385A (ja) 2021-04-09 2024-06-19 ヴァルネヴァ エスイー ヒトメタニューモウイルスワクチン
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4761372A (en) 1981-01-12 1988-08-02 New York University Mutant enterotoxin of E. coli
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5308835A (en) 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
AUPO264096A0 (en) 1996-09-30 1996-10-24 Mclaughlin Geosurveys Pty Ltd. Value improvement of clays
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
CA2301000C (en) 1997-08-28 2003-07-08 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
CA2437899C (en) 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20110189217A1 (en) * 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
CN101734698B (zh) 2009-09-08 2013-01-09 东北大学 一种由含铝物料制备氧化铝的方法
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines

Also Published As

Publication number Publication date
EP2788023A1 (en) 2014-10-15
DK3785730T3 (da) 2024-05-06
HUE037325T2 (hu) 2018-08-28
EP3785730A1 (en) 2021-03-03
DE202012012768U1 (de) 2014-01-21
EP3785730B1 (en) 2024-04-24
DK201300194U1 (da) 2014-01-17
RS56709B1 (sr) 2018-03-30
EP3269386B1 (en) 2022-09-14
ES2647882T3 (es) 2017-12-27
EP2788023B1 (en) 2016-11-02
HRP20171871T1 (hr) 2018-01-12
EP3106176A1 (en) 2016-12-21
PT3106176T (pt) 2017-12-20
DK3106176T3 (da) 2018-01-08
EP4400115A2 (en) 2024-07-17
EP3269386A1 (en) 2018-01-17
DK2788023T3 (da) 2016-12-19
DK3269386T3 (da) 2022-10-24
PL3269386T3 (pl) 2022-12-05
LT3106176T (lt) 2018-01-10
NO3106176T3 (da) 2018-03-10
PL3106176T3 (pl) 2018-03-30
EP3106176B1 (en) 2017-10-11
CY1119927T1 (el) 2018-12-12
PT3269386T (pt) 2022-12-05
SI3106176T1 (en) 2018-04-30
FI3785730T3 (fi) 2024-05-06
ES2930458T3 (es) 2022-12-13
WO2013083726A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
DK201300193U1 (da) Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner.
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
CY1121736T1 (el) Άλατα aramchol
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
PH12015502441B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
UY33802A (es) Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
WO2014108846A3 (en) Soothing cosmetic composition based on salicylic acid
FR2991876B1 (fr) Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
EA201492091A1 (ru) Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
IN2013MU03773A (da)
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
EA201892563A1 (ru) Композиция для местного применения
EA201590752A1 (ru) Препараты производных пиримидиндиона

Legal Events

Date Code Title Description
UBP Utility model lapsed

Effective date: 20160104